190 related articles for article (PubMed ID: 37384449)
1. Calcium Orthophosphate in Liposomes for Co-Delivery of Doxorubicin Hydrochloride/Paclitaxel in Breast Cancer.
Chen X; He H; Guo X; Hou M; Zhang X; Li S; Wang C; Zhao G; Li W; Zhang X; Hong W
Mol Pharm; 2023 Aug; 20(8):3914-3924. PubMed ID: 37384449
[TBL] [Abstract][Full Text] [Related]
2. Tailored design of multifunctional and programmable pH-responsive self-assembling polypeptides as drug delivery nanocarrier for cancer therapy.
Wang TW; Yeh CW; Kuan CH; Wang LW; Chen LH; Wu HC; Sun JS
Acta Biomater; 2017 Aug; 58():54-66. PubMed ID: 28606810
[TBL] [Abstract][Full Text] [Related]
3. High Tumor Penetration of Paclitaxel Loaded pH Sensitive Cleavable Liposomes by Depletion of Tumor Collagen I in Breast Cancer.
Zhang L; Wang Y; Yang Y; Liu Y; Ruan S; Zhang Q; Tai X; Chen J; Xia T; Qiu Y; Gao H; He Q
ACS Appl Mater Interfaces; 2015 May; 7(18):9691-701. PubMed ID: 25845545
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
5. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
Haque ST; Islam RA; Gan SH; Chowdhury EH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
[No Abstract] [Full Text] [Related]
6. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
7. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
8. Designed Synthesis of Lipid-Coated Polyacrylic Acid/Calcium Phosphate Nanoparticles as Dual pH-Responsive Drug-Delivery Vehicles for Cancer Chemotherapy.
Wang X; Zhang M; Zhang L; Li L; Li S; Wang C; Su Z; Yuan Y; Pan W
Chemistry; 2017 May; 23(27):6586-6595. PubMed ID: 28218434
[TBL] [Abstract][Full Text] [Related]
9. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645
[TBL] [Abstract][Full Text] [Related]
10. Novel Core-Interlayer-Shell DOX/ZnPc Co-loaded MSNs@ pH-Sensitive CaP@PEGylated Liposome for Enhanced Synergetic Chemo-Photodynamic Therapy.
Ma J; Wu H; Li Y; Liu Z; Liu G; Guo Y; Hou Z; Zhao Q; Chen D; Zhu X
Pharm Res; 2018 Feb; 35(3):57. PubMed ID: 29423532
[TBL] [Abstract][Full Text] [Related]
11. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN
Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Cellular Internalization and On-Demand Intracellular Release of Doxorubicin by Stepwise pH-/Reduction-Responsive Nanoparticles.
Li F; Chen WL; You BG; Liu Y; Yang SD; Yuan ZQ; Zhu WJ; Li JZ; Qu CX; Zhou YJ; Zhou XF; Liu C; Zhang XN
ACS Appl Mater Interfaces; 2016 Nov; 8(47):32146-32158. PubMed ID: 27933846
[TBL] [Abstract][Full Text] [Related]
13. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X
Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.
Mattu C; Pabari RM; Boffito M; Sartori S; Ciardelli G; Ramtoola Z
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):463-72. PubMed ID: 23916461
[TBL] [Abstract][Full Text] [Related]
15. Ligand-Modified Erythrocyte Membrane-Cloaked Metal-Organic Framework Nanoparticles for Targeted Antitumor Therapy.
Lin Y; Zhong Y; Chen Y; Li L; Chen G; Zhang J; Li P; Zhou C; Sun Y; Ma Y; Xie Z; Liao Q
Mol Pharm; 2020 Sep; 17(9):3328-3341. PubMed ID: 32804508
[TBL] [Abstract][Full Text] [Related]
16. Folate-receptor mediated pH/reduction-responsive biomimetic nanoparticles for dually activated multi-stage anticancer drug delivery.
Wang D; Chen W; Li H; Huang G; Zhou Y; Wang Y; Wan W; You B; Liu Y; Zhang X
Int J Pharm; 2020 Jul; 585():119456. PubMed ID: 32492507
[TBL] [Abstract][Full Text] [Related]
17. PEGylated-PLGA Nanoparticles Coated with pH-Responsive Tannic Acid-Fe(III) Complexes for Reduced Premature Doxorubicin Release and Enhanced Targeting in Breast Cancer.
Hu F; Zhang R; Guo W; Yan T; He X; Hu F; Ren F; Ma X; Lei J; Zheng W
Mol Pharm; 2021 Jun; 18(6):2161-2173. PubMed ID: 32515968
[TBL] [Abstract][Full Text] [Related]
18. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
Zhang Q; Tang J; Fu L; Ran R; Liu Y; Yuan M; He Q
Biomaterials; 2013 Oct; 34(32):7980-93. PubMed ID: 23891517
[TBL] [Abstract][Full Text] [Related]
19. Smart Lipid-Polysaccharide Nanoparticles for Targeted Delivery of Doxorubicin to Breast Cancer Cells.
Curcio M; Brindisi M; Cirillo G; Frattaruolo L; Leggio A; Rago V; Nicoletta FP; Cappello AR; Iemma F
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216501
[TBL] [Abstract][Full Text] [Related]
20. pH-temperature dual-sensitive nucleolipid-containing stealth liposomes anchored with PEGylated AuNPs for triggering delivery of doxorubicin.
García MC; Calderón-Montaño JM; Rueda M; Longhi M; Rabasco AM; López-Lázaro M; Prieto-Dapena F; González-Rodríguez ML
Int J Pharm; 2022 May; 619():121691. PubMed ID: 35331830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
